Compare MD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | BEAM |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 1996 | 2019 |
| Metric | MD | BEAM |
|---|---|---|
| Price | $25.91 | $24.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $20.50 | ★ $50.75 |
| AVG Volume (30 Days) | 638.9K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 82.31 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $1,913,849,000.00 | $24,000.00 |
| Revenue This Year | $3.72 | N/A |
| Revenue Next Year | $2.62 | $33.77 |
| P/E Ratio | $31.21 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $15.70 | $20.23 |
| 52 Week High | $28.86 | $38.26 |
| Indicator | MD | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 32.83 |
| Support Level | $25.24 | $21.63 |
| Resistance Level | $27.23 | $28.87 |
| Average True Range (ATR) | 0.79 | 1.25 |
| MACD | -0.04 | -0.63 |
| Stochastic Oscillator | 53.81 | 6.66 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.